Starpharma company secretary retires this week


By Dylan Bushell-Embling
Tuesday, 10 December, 2013

Starpharma (ASX:SPL) has announced the imminent retirement of long-serving company secretary Ben Rogers.

Rogers will be replaced on Friday by Starpharma CFO Nigel Baade, who has been with the company for seven years.

Starpharma CEO Dr Jackie Fairley said Rogers and Baade have been working together closely for the past seven years, meaning the transition should be painless.

“As an executive team we have worked closely with Ben over many years and the executive and the board thank him for his valuable contribution,” Fairley said. “We are fortunate to have had a natural choice in Nigel to succeed Ben in the position of Company Secretary.”

In September, Starpharma revealed it was developing a new dendrimer-enhanced chemotherapy drug, dendrimer oxaliplatin. The company’s first dendrimer-enhanced chemotherapy, dendrimer docetaxel, is at the phase I trial stage.

Starpharma (ASX:SPL) shares were trading 2.26% lower at $0.777 as of around 1 pm on Tuesday.

Related News

The University of Sydney formalises cervical cancer elimination partnership

The success of a cervical cancer elimination program has led to the signing of a memorandum of...

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd